Interim report January - September 2009

Interim report January - September 2009 

• Group revenues from sales of goods and royalties amounted to 1,016 (936) MSEK.


• Earnings per share amounted to 6.38 (0.78) SEK. 

• Operating income amounted to 676 (100) MSEK. 

• In April 2009 Q-Med AB and Oceana Therapeutics, LCC., based in the US, entered
into global agreements regarding commercialization rights to Deflux® and
Solesta™. The agreements gave Q-Med an initial payment of 517 MSEK in total in
June, partly as a purchase sum for Q-Med Scandinavia, Inc., the subsidiary that
was divested within the framework of the agreements, and partly as payment for
Oceana's share of certain study costs. The net revenue of 496 MSEK has been
recorded in the Group income statement in the Other operating revenues row.

• Revenues within the Esthetics product area amounted to 846 (765) MSEK and
operating income was 195 (177) MSEK. For the Hospital Healthcare product area
revenues from sales of goods and royalties were 170 (171) MSEK and operating
income was 537 (-22) MSEK. Operating income includes the net revenue from the
Oceana deal.

• Net income after tax amounted to 634 (77) MSEK.

July - September
• Group revenues from sales of goods and royalties amounted to 295 (306) MSEK
during the third quarter and operating income amounted to 51 (61) MSEK.
Operating income for the Esthetics product area amounted to 53 (59) MSEK and for
the Hospital Healthcare product area operating income amounted to 18 (8) MSEK.

• Net income after tax amounted to 42 (45) MSEK during the third quarter.

• When the FDA advisory committee (Orthopaedic and Rehabilitation Devices
Advisory Committee) in the USA met on August 19, 2009, further information was
requested in order to be able to recommend Premarket Approval, PMA for
DurolaneTM. Together with its partner, Smith & Nephew, Q-Med is now continuing
to work with the FDA to provide the information necessary for Premarket
Approval.  

• As Q-Med's revenues during July and August 2009 were considerably lower than
during the same period in 2008, Q-Med issued a press release on September 18,
2009 with an update regarding the development of Q-Med's sales and results. If
sales during September had continued at the same rate as during July and August,
revenues for the third quarter would have been approximately 20 percent lower
than for the corresponding period in 2008. However, during September 2009 sales
revenues increased substantially compared to July and August. At the end of the
third quarter sales revenues were only 5 percent lower, 286 (302) MSEK, compared
to the same period in 2008.

Queries should be addressed to:
Bengt Ågerup, President and CEO
Tel: +46 70 974 9025 

Alexander Kotsinas, Vice President and CFO
Tel: +46 73-500 1111

Karin Falck, Director Investor Relations and Corporate Communications
Tel: +46 70-974 9015

Q-Med AB is a medical device company. The company develops, manufactures,
markets, and sells primarily medical implants. The majority of the products are
based on the company's patented technology, NASHA™, for the production of
stabilized non-animal hyaluronic acid. The product portfolio today contains:
Restylane® for filling lines and folds, contouring and creating volume in the
face, Macrolane™ for body shaping, Durolane™ for the treatment of osteoarthritis
of the hip and knee joints, Deflux® for the treatment of vesicoureteral reflux,
VUR, (a malformation of the urinary bladder) in children, and Solesta™ for the
treatment of fecal incontinence. Sales are made through the company's own
subsidiaries or distributors in over 70 countries. Q Med today has approximately
650 coworkers, with close to 400 at the company's head office and production
facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of NASDAQ
OMX Nordic.